Molecular structure of Isradipine, CAS Number: 75695-93-1
Isradipine (CAS 75695-93-1)
See product citations (1)
Application:
Isradipine is a selective agonist and calcium channel protein inhibitor
CAS Number:
75695-93-1
Purity:
≥98%
Molecular Weight:
371.4
Molecular Formula:
C19H21N3O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Isradipine is a 2,4-dihydropyridine selective agonist and calcium channel protein inhibitor. Research has indicated that Isradipine has anti-atherosclerotic effects in animals and improves endothelium-mediated nitric oxide (NO)-dependent vasodilation in vitro. Additional studies indicate that Isradipine may provide a neuroprotective effect in a rat model of focal ischemia and that Isradipine produces a dose-dependent sparing of dopamine neuronal fibers and cell bodies.
Isradipine (CAS 75695-93-1) References
- Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia. | Chandra, S., et al. 1999. Pharmacology. 58: 292-9. PMID: 10325574
- Isradipine and insulin sensitivity in hypertensive rats. | Pĭtre, M., et al. 1999. Am J Physiol. 276: E1038-48. PMID: 10362616
- Isradipine improves endothelium-dependent vasodilation in normotensive coronary artery disease patients with hypercholesterolemia. | Bracht, C., et al. 2001. J Hypertens. 19: 899-905. PMID: 11393673
- Isradipine prevents the development of spontaneously occurring cardiac necrosis in cardiomyopathic hamster. | Jacques, D., et al. 2003. Can J Physiol Pharmacol. 81: 120-4. PMID: 12710524
- The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. | Ilijic, E., et al. 2011. Neurobiol Dis. 43: 364-71. PMID: 21515375
- Effect of hydrophilic polymers on isradipine complexation with hydroxypropyl β-cyclodextrin. | Mummidi, V. and Jayanthi, V. 2013. Drug Dev Ind Pharm. 39: 970-7. PMID: 22612875
- Isradipine prevents rotenone-induced intracellular calcium rise that accelerates senescence in human neuroblastoma SH-SY5Y cells. | Yu, X., et al. 2013. Neuroscience. 246: 243-53. PMID: 23664925
- Amorphous isradipine nanosuspension by the sonoprecipitation method. | Tran, TT., et al. 2014. Int J Pharm. 474: 146-50. PMID: 25138256
- Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease. | Ortner, NJ., et al. 2017. J Neurosci. 37: 6761-6777. PMID: 28592699
- L-type calcium channel antagonist isradipine age-dependently decreases plaque associated dystrophic neurites in 5XFAD mouse model. | Wickline, JL., et al. 2023. Neuropharmacology. 227: 109454. PMID: 36740015
- Isradipine suppresses amphetamine-induced conditioned place preference and locomotor stimulation in the rat. | Pucilowski, O., et al. 1995. Neuropsychopharmacology. 12: 239-44. PMID: 7612157
- Effect of isradipine on the formation and regression of fatty streaks in cholesterol fed rabbits. | Kunjara-Na-Ayudhya, R., et al. 1994. Cardiovasc Res. 28: 1089-95. PMID: 7954596
- Isradipine inhibits nicotine intravenous self-administration in drug-naive mice. | Martellotta, MC., et al. 1995. Pharmacol Biochem Behav. 52: 271-4. PMID: 8577790
Inhibitor of:
CA II, CA XI, CaBP2, Cacna2d1, Cacna2d3, Cacna2d4, Calcium Channel Protein, calsequestrin 2, CAPS-2, CLCA2_Clac2, L-type Ca++ CP α1C, L-type Ca++ CP α1C/1D/1F/1S, L-type Ca++ CP α1D, L-type Ca++ CP α1F, L-type Ca++ CP α1S, L-type Ca++ CP β1, L-type Ca++ CP β2, L-type Ca++ CP β4, L-type Ca++ CP γ1, L-type Ca++ CP γ2, L-type Ca++ CP γ4, L-type Ca++ CP γ5, L-type Ca++ CP γ6, L-type Ca++ CP γ7, L-type Ca++ CP γ8, L-type calcium channel α1C, L-type calcium channel α1D, L-type calcium channel α1F, L-type calcium channel β1, L-type Calcium Channel γ, N-type Ca CP α1B, N-type Ca++ CP α1B, Na+ CP type Iβ, Na+ CP type VIIα, NCKX2, NCKX4, NCKX5, NFATc3, Olfr769, Olr1233, Olr1595, Olr400, Raftlin, SCRN1, T-type Ca++ CP α1G, TRAP-δ, Troponin C slow skeletal, and VILIP-3.Activator of:
Cacna2d4, CAPS1, DREAM, GCAP2, GCC1, KChIP4, KCNMB3, KRCC1, L-type Ca++ CP β3, L-type Ca++ CP γ2, L-type Ca++ CP γ3, L-type Ca++ CP γ4, L-type Ca++ CP γ5, L-type Ca++ CP γ7, L-type calcium channel α1C, L-type calcium channel α1D, L-type calcium channel α1F, L-type calcium channel β1, NCKX1, NCKX6, NCX1, P/Q-type Ca++ CP α1A, P/Q-type calcium channel α1A, parvalbumin α, R-type Ca++ CP α1E, Recoverin, Slc22a22, T-type Ca++ CP α1G, T-type Ca++ CP α1I, and T-type calcium channel α1G.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Isradipine, 10 mg | sc-201467 | 10 mg | $88.00 | |||
Isradipine, 50 mg | sc-201467A | 50 mg | $324.00 |